huahaipharm(SH:600521) Xin Lang Zheng Quan·2025-09-25 05:34Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 24.17%, indicating volatility in market performance [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 19, 2025, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - The top ten circulating shareholders include notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - The stock's trading volume on September 25 was 532 million yuan, with a turnover rate of 1.61% and a total market capitalization of 32.76 billion yuan [1]. - Huahai Pharmaceutical has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 9, where it recorded a net buy of -53.101 million yuan [1]. Business Overview - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1]. - The company's revenue composition includes finished drug sales (61.86%), raw materials and intermediates sales (36.75%), and other services [1]. Industry Classification - Huahai Pharmaceutical is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations, with involvement in AI medicine, generic drugs, innovative drugs, cell therapy, and biomedicine [2].